Literature DB >> 22498473

A competing risk approach for the European Heart SCORE model based on cause-specific and all-cause mortality.

Henrik Støvring1, Charlotte G Harmsen, Torbjørn Wisløff, Dorte E Jarbøl, Jørgen Nexøe, Jesper B Nielsen, Ivar S Kristiansen.   

Abstract

BACKGROUND: The European Heart SCORE model constitutes the basis for national guidelines for primary prevention and treatment of cardiovascular disease (CVD) in several European countries. The model estimates individuals' 10-year CVD mortality risks from age, sex, smoking status, systolic blood pressure, and total cholesterol level. The SCORE model, however, is not mathematically consistent and does not estimate all-cause mortality. Our aim is to modify the SCORE model to allow consistent estimation of both CVD-specific and all-cause mortality.
METHODS: Using a competing risk approach, we first re-estimated the cause-specific risk of dying from cardiovascular disease, and secondly we incorporated non-CVD mortality. Finally, non-CVD mortality was allowed to also depend on smoking status, and not only age and sex. From the models, we estimated CVD-specific and all-cause 10-year mortality risk, and the expected residual lifetime together with corresponding expected effects of statin treatment.
RESULTS: The modified model provided CVD-specific 10-year mortality risks similar to those of the European Heart SCORE model. Incorporation of non-CVD mortality increased 10-year mortality risks, in particular for older individuals. When non-CVD mortality was assumed unaffected by smoking status, the absolute risk reduction due to statin treatment ranged from 0.0% to 3.5%, whereas the gain in expected residual lifetime ranged from 3 to 11 months. Statin effectiveness increased for non-smokers and declined for smokers, when smoking was allowed to influence non-CVD mortality.
CONCLUSION: The modified model provides mathematically consistent estimates of mortality risk and expected residual lifetime together with expected benefits from statin treatment.

Entities:  

Keywords:  Absolute risk reduction; cardiovascular mortality; competing risk model; prolongation of life; risk prediction

Mesh:

Substances:

Year:  2012        PMID: 22498473     DOI: 10.1177/2047487312445425

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  10 in total

1.  Communicating risk using absolute risk reduction or prolongation of life formats: cluster-randomised trial in general practice.

Authors:  Charlotte Gry Harmsen; Ivar Sønbø Kristiansen; Pia Veldt Larsen; Jørgen Nexøe; Henrik Støvring; Dorte Gyrd-Hansen; Jesper Bo Nielsen; Adrian Edwards; Dorte Ejg Jarbøl
Journal:  Br J Gen Pract       Date:  2014-04       Impact factor: 5.386

2.  Postponement of Death by Statin Use: a Systematic Review and Meta-analysis of Randomized Clinical Trials.

Authors:  Morten Rix Hansen; Asbjørn Hróbjartsson; Anton Pottegård; Per Damkier; Kasper Søltoft Larsen; Kenneth Grønkjær Madsen; René dePont Christensen; Malene Elisa Lopez Kristensen; Palle Mark Christensen; Jesper Hallas
Journal:  J Gen Intern Med       Date:  2019-05-09       Impact factor: 5.128

3.  Adherence to preventive statin therapy according to socioeconomic position.

Authors:  Helle Wallach-Kildemoes; Morten Andersen; Finn Diderichsen; Theis Lange
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

4.  Decisions on statin therapy by patients' opinions about survival gains: cross sectional survey of general practitioners.

Authors:  Peder A Halvorsen; Olaf Gjerløw Aasland; Ivar Sønbø Kristiansen
Journal:  BMC Fam Pract       Date:  2015-07-03       Impact factor: 2.497

5.  Algorithm for predicting CHD death risk in Turkish adults: conventional factors contribute only moderately in women.

Authors:  Altan Onat; Günay Can; Ayşem Kaya; Muhammed Keskin; Mert I Hayıroğlu; Hüsniye Yüksel
Journal:  Anatol J Cardiol       Date:  2017-03-09       Impact factor: 1.596

6.  The Future of Health Is Self-Production and Co-Creation Based on Apomediative Decision Support.

Authors:  Jack Dowie; Mette Kjer Kaltoft
Journal:  Med Sci (Basel)       Date:  2018-08-22

7.  Performance of risk prediction scores for cardiovascular mortality in older persons: External validation of the SCORE OP and appraisal.

Authors:  Marco Piccininni; Jessica L Rohmann; Dörte Huscher; Nina Mielke; Natalie Ebert; Giancarlo Logroscino; Elke Schäffner; Tobias Kurth
Journal:  PLoS One       Date:  2020-04-09       Impact factor: 3.240

8.  Generalizability of Cardiovascular Disease Clinical Prediction Models: 158 Independent External Validations of 104 Unique Models.

Authors:  Gaurav Gulati; Jenica Upshaw; Benjamin S Wessler; Riley J Brazil; Jason Nelson; David van Klaveren; Christine M Lundquist; Jinny G Park; Hannah McGinnes; Ewout W Steyerberg; Ben Van Calster; David M Kent
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2022-03-31

9.  Impact of effectiveness information format on patient choice of therapy and satisfaction with decisions about chronic disease medication: the "Influence of intervention Methodologies on Patient Choice of Therapy (IMPACT)" cluster-randomised trial in general practice.

Authors:  Charlotte Gry Harmsen; Dorte Ejg Jarbøl; Jørgen Nexøe; Henrik Støvring; Dorte Gyrd-Hansen; Jesper Bo Nielsen; Adrian Edwards; Ivar Sønbø Kristiansen
Journal:  BMC Health Serv Res       Date:  2013-02-25       Impact factor: 2.655

10.  The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials.

Authors:  Janus Christian Jakobsen; Christian Gluud; Per Winkel; Theis Lange; Jørn Wetterslev
Journal:  BMC Med Res Methodol       Date:  2014-03-04       Impact factor: 4.615

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.